Research on breast cancer markers in tissue and fluid samples
Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum
This study is trying to find specific markers in tissue and fluid samples from breast cancer patients to see if they can improve blood tests for diagnosing and predicting breast cancer outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Trial ID | NCT01042548 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify distinct breast cancer profiles by comparing tissue interstitial fluid from breast cancer patients with adjacent non-cancerous tissue and benign breast lesions. It involves collecting fresh samples from patients undergoing surgery for breast nodules or newly diagnosed invasive breast cancer. The research will analyze these samples to discover proteomic markers that could lead to improved blood tests for breast cancer diagnosis and prognosis. Additionally, it will gather clinical and demographic data to enhance understanding of breast cancer outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are undergoing surgery for indeterminate breast nodules or have newly diagnosed invasive breast cancer.
Not a fit: Patients under 18 years of age or those with multiple synchronous primary malignancies from different organ systems may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to the development of more accurate diagnostic and prognostic blood tests for breast cancer.
How similar studies have performed: Other studies have shown promise in using proteomics and radiomics for cancer marker identification, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All subjects ≥ 18 years of age undergoing surgery for indeterminate breast nodules, breast tissue reduction, prophylactic mastectomy, and all subjects with newly diagnosed invasive breast cancer will be eligible to participate. If invasive breast cancer or suspicion of invasive breast cancer, target lesion must measure ≥ 1.0 cm on breast imaging before core biopsy. Exclusion Criteria: * Anyone \< 18 years of age. * Multiple synchronous primary malignancies from different organ systems.
Where this trial is running
Pittsburgh, Pennsylvania
- UPMC St. Margaret — Pittsburgh, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: Laura Chiesa
- Email: powersl2@upmc.edu
- Phone: 412-831-1320
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.